[go: up one dir, main page]

HRP20040587B1 - Injection solution comprising an lhrh antagonist - Google Patents

Injection solution comprising an lhrh antagonist

Info

Publication number
HRP20040587B1
HRP20040587B1 HR20040587A HRP20040587A HRP20040587B1 HR P20040587 B1 HRP20040587 B1 HR P20040587B1 HR 20040587 A HR20040587 A HR 20040587A HR P20040587 A HRP20040587 A HR P20040587A HR P20040587 B1 HRP20040587 B1 HR P20040587B1
Authority
HR
Croatia
Prior art keywords
lhrh antagonist
gluconic acid
injection solution
adjuvant
surfactant
Prior art date
Application number
HR20040587A
Other languages
Croatian (hr)
Inventor
Sarlikiotis Werner
Bauer Horst
Rischer Matthias
G�thlein Frank
Engel J�rgen
Di Stefano Dominique
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of HRP20040587A2 publication Critical patent/HRP20040587A2/en
Publication of HRP20040587B1 publication Critical patent/HRP20040587B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

Vodena otopina za uštrcavanje LHRH antagonista koja sadrži glukonsku kiselinu, po izboru surfaktanti pomoćno sredstvo, naznačena time, da se kao LHRH antagonist koriste cetrorelix, teverelix, D-63 153 (Ac-D-Nal-pCl-D-Phe-3-D-Pal-Ser-N-Me-Tyr-D-H-Cit-Iso-Leu-Arg-Pro-D-Ala-NH2), ganirelix, abarelix,antide ili azaline B i da je glukonska kiselina nazočna u iznosu koji je veći od ekvimolarnog, temeljeno na količini LHRH antagonista, da se glukonska kiselina dodaje u obliku glukonska kiselina delta-lakton, te da se po izboru Tween 80 rabi kao surfaktant, a mannitol kao pomoćno sredstvo. Patent sadrži još 4 patentna zahtjeva.Aqueous solution for injecting LHRH antagonist containing gluconic acid, optionally a surfactant adjuvant, characterized in that cetrorelix, teverelix, D-63 153 (Ac-D-Nal-pCl-D-Phe-3-D) are used as LHRH antagonist -Pal-Ser-N-Me-Tyr-DH-Cit-Iso-Leu-Arg-Pro-D-Ala-NH2), ganirelix, abarelix, antide or azaline B and that gluconic acid is present in an amount greater than equimolar, based on the amount of LHRH antagonist, that gluconic acid is added in the form of delta-lactone gluconic acid, and optionally Tween 80 is used as a surfactant and mannitol as an adjuvant. The patent contains 4 more patent claims.

HR20040587A 2001-11-26 2002-11-15 Injection solution comprising an lhrh antagonist HRP20040587B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10157628A DE10157628A1 (en) 2001-11-26 2001-11-26 Solution for injection of an LHRH antagonist
PCT/EP2002/012798 WO2003045419A1 (en) 2001-11-26 2002-11-15 Injection solution comprising an lhrh antagonist

Publications (2)

Publication Number Publication Date
HRP20040587A2 HRP20040587A2 (en) 2004-10-31
HRP20040587B1 true HRP20040587B1 (en) 2008-01-31

Family

ID=7706799

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040587A HRP20040587B1 (en) 2001-11-26 2002-11-15 Injection solution comprising an lhrh antagonist

Country Status (32)

Country Link
EP (1) EP1448221B1 (en)
JP (1) JP4343693B2 (en)
KR (1) KR100936636B1 (en)
CN (1) CN100404068C (en)
AR (1) AR037424A1 (en)
AT (1) ATE350050T1 (en)
AU (1) AU2002365504B2 (en)
BR (1) BRPI0214412B8 (en)
CO (1) CO5580793A2 (en)
CY (1) CY1106401T1 (en)
DE (2) DE10157628A1 (en)
DK (1) DK1448221T3 (en)
EA (1) EA010787B1 (en)
ES (1) ES2276970T3 (en)
GE (1) GEP20063861B (en)
HR (1) HRP20040587B1 (en)
HU (1) HU230992B1 (en)
IL (2) IL161894A0 (en)
IS (1) IS2725B (en)
ME (1) ME00499B (en)
MX (1) MXPA04005018A (en)
NO (1) NO333364B1 (en)
NZ (1) NZ533712A (en)
PL (1) PL206199B1 (en)
PT (1) PT1448221E (en)
RS (1) RS51408B (en)
RU (1) RU2322969C2 (en)
SI (1) SI1448221T1 (en)
TW (1) TWI312283B (en)
UA (1) UA81612C2 (en)
WO (1) WO2003045419A1 (en)
ZA (1) ZA200404051B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
ES2426445T3 (en) 2006-04-07 2013-10-23 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
BRPI0912384A2 (en) * 2008-05-07 2015-10-13 Merrion Res Iii Ltd composition and method for preparing a composition
WO2011120033A1 (en) 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
US8802114B2 (en) 2011-01-07 2014-08-12 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
CN103690560B (en) * 2013-12-17 2016-08-17 辽宁海思科制药有限公司 A kind of Invert sugar electrolyte injection pharmaceutical composition and preparation method thereof
US10265384B2 (en) 2015-01-29 2019-04-23 Novo Nordisk A/S Tablets comprising GLP-1 agonist and enteric coating
RU2614234C2 (en) * 2015-03-31 2017-03-23 Федеральное государственное бюджетное учреждение науки Институт общей генетики им. Н.И. Вавилова Российской академии наук (ИОГЕН РАН) PHARMACEUTICAL COMPOSITION BASED ON 3-(4-METHYLIMIDAZOLE-1-YL)IMIDAZO[1,2-b][1,2,4,5]TETRAZINE AS ANTI-TUMOR AGENT
EP3701965A1 (en) * 2017-01-30 2020-09-02 Antev Limited A composition comprising at least one gnrh antagonist
HUE058963T2 (en) 2019-10-24 2022-10-28 Sun Pharmaceutical Ind Ltd A stable parenteral dosage form of cetrorelix acetate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021194A2 (en) * 1999-09-23 2001-03-29 Zentaris Ag Method for the therapeutic management of endometriosis and fallopian tube obstruction
WO2001087265A2 (en) * 2000-05-18 2001-11-22 Zentaris Ag Pharmaceutical form of administration for peptides, methods for its production and use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
US5300492A (en) * 1988-02-10 1994-04-05 Tap Pharmaceuticals LHRH analogs
US5140009A (en) * 1988-02-10 1992-08-18 Tap Pharmaceuticals, Inc. Octapeptide LHRH antagonists
DE4305225A1 (en) * 1993-02-19 1994-08-25 Asta Medica Ag New manufacturing process for Cetrorelix lyophilisate

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021194A2 (en) * 1999-09-23 2001-03-29 Zentaris Ag Method for the therapeutic management of endometriosis and fallopian tube obstruction
WO2001087265A2 (en) * 2000-05-18 2001-11-22 Zentaris Ag Pharmaceutical form of administration for peptides, methods for its production and use

Also Published As

Publication number Publication date
BRPI0214412B8 (en) 2021-05-25
KR20040058312A (en) 2004-07-03
HUP0401986A2 (en) 2005-01-28
HRP20040587A2 (en) 2004-10-31
ZA200404051B (en) 2005-05-25
SI1448221T1 (en) 2007-06-30
BR0214412A (en) 2004-09-14
CN100404068C (en) 2008-07-23
BRPI0214412B1 (en) 2016-01-05
NO333364B1 (en) 2013-05-13
HU230992B1 (en) 2019-08-28
DE50209193D1 (en) 2007-02-15
PL369548A1 (en) 2005-05-02
GEP20063861B (en) 2006-06-26
JP4343693B2 (en) 2009-10-14
AR037424A1 (en) 2004-11-10
MXPA04005018A (en) 2004-08-11
IL161894A (en) 2014-05-28
WO2003045419A1 (en) 2003-06-05
DE10157628A1 (en) 2003-06-12
HUP0401986A3 (en) 2012-09-28
IL161894A0 (en) 2005-11-20
KR100936636B1 (en) 2010-01-14
PL206199B1 (en) 2010-07-30
CO5580793A2 (en) 2005-11-30
RU2322969C2 (en) 2008-04-27
RS51408B (en) 2011-02-28
ME00499B (en) 2011-10-10
EP1448221B1 (en) 2007-01-03
JP2005510544A (en) 2005-04-21
CY1106401T1 (en) 2011-10-12
NO20042449L (en) 2004-06-11
IS2725B (en) 2011-03-15
EP1448221A1 (en) 2004-08-25
CN1592630A (en) 2005-03-09
RU2004119821A (en) 2005-04-20
TWI312283B (en) 2009-07-21
TW200300352A (en) 2003-06-01
AU2002365504A1 (en) 2003-06-10
EA200400742A1 (en) 2004-12-30
UA81612C2 (en) 2008-01-25
PT1448221E (en) 2007-03-30
ES2276970T3 (en) 2007-07-01
NZ533712A (en) 2006-01-27
DK1448221T3 (en) 2007-03-19
IS7251A (en) 2004-05-06
HK1073078A1 (en) 2005-09-23
AU2002365504B2 (en) 2007-06-28
EA010787B1 (en) 2008-10-30
RS44904A (en) 2006-10-27
ATE350050T1 (en) 2007-01-15

Similar Documents

Publication Publication Date Title
HRP20040587B1 (en) Injection solution comprising an lhrh antagonist
AR033059A1 (en) INSULIN PREPARED EXEMPT FROM ZINC AND POOR IN ZINC, WITH IMPROVED STABILITY.
MEP28708A (en) Acidic insulin preparations with improved stability
CO4890855A1 (en) AQUEOUS FORMULATIONS OF PEPTIDES
DOP2001000197A (en) STABILIZED INTERLEUQUINA-2
PE84899A1 (en) PHARMACEUTICAL FORMULATIONS CONTAINING VORICONAZOLE
ATE287705T1 (en) HEAT-GELELLING BIODEGRADABLE AQUEOUS POLYMER SOLUTION
ES2190087T3 (en) STABILIZED FORMULATION OF AN ANTIBODY.
AR022009A1 (en) HERBICIDE COMPOSITIONS
ES2187782T3 (en) PROCEDURE FOR THE PRODUCTION OF POLYPEPTIDES.
CA2412759A1 (en) Injectable solution of an lhrh antagonist
ATE288471T1 (en) LIQUID CLEANING OR DETERGENT COMPOSITION
BR0304298A (en) Composition containing a cosmetically active organic acid and a vegetable product
ES2140667T3 (en) DETERGENT COMPOSITIONS.
DE69029472D1 (en) IMPROVED AQUEOUS AQUEOUS CLEANING / DEGREASING MICROEMULSION COMPOSITIONS
IL155788A (en) Composition comprising biologically active ifn--beta and highly purified mannitol, a method of producing a formulation of biologically active ifn-beta having improved stability and a method for increasing the stability of biologically active ifn-beta in a composition
DK0832107T3 (en) Enhanced peptide, immunogenic composition and vaccine or medical preparation, method of immunizing animals against the hormone LHRH as well as analogues of the LHRH tandem peptide repeat peptide and their use as a vaccine
RS49511B (en) SUSPENSION OF CONTINUOUS SUSPENSION AND PROCEDURE FOR THE PRODUCTION OF THE SAME
MXPA04003540A (en) Use of a copolymer to produce a galenic form containing a peptide or a protein as active agent.
BR9607812A (en) Cleaning compositions
CO5540279A2 (en) LIOFILITATED FORMULATION OF 2-METHYL-TIENO-BENZODIAZEPINA
ES2119405T3 (en) DETERGENT COMPOSITIONS.
TR200100387T2 (en) Pesticide formulations containing alkoxylated amine neutralized aromatic sulfonic acid surfactants
RU2003107560A (en) PEPTIDE SALT (OPTIONS), METHOD FOR PRODUCING AND USE, PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING IT
WO2002057246A3 (en) Inhibitors of cruzipain and other cysteine proteases

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: ZENTARIS GMBH, DE

B1PR Patent granted
PNAN Change of the applicant name, address/residence

Owner name: AETERNA ZENTARIS GMBH, DE

PPPP Transfer of rights

Owner name: ZENTARIS IVF GMBH, DE

ODRP Renewal fee for the maintenance of a patent

Payment date: 20181108

Year of fee payment: 17

ODRP Renewal fee for the maintenance of a patent

Payment date: 20191024

Year of fee payment: 18

ODRP Renewal fee for the maintenance of a patent

Payment date: 20201110

Year of fee payment: 19

ODRP Renewal fee for the maintenance of a patent

Payment date: 20211111

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20221115